ArticleScience translational medicine2021
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of
Abstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.Scientific reports · 2026Pooled it
- MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib-Resistant MET-Amplified, EGFR-Mutated Non-Small Cell Lung Cancer.Thoracic cancer · 2026Article
- Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.Nature communications · 2025Article
- New advances in the treatment of EGFR exon20ins mutant advanced NSCLC.American journal of cancer research · 2025Review
- [Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Article
- An "AND" logic gate-based supramolecular therapeutic nanoplatform for combatting drug-resistant non-small cell lung cancer.Science advances · 2024Article
- Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.Cancer research communications · 2024Article
- Spatial Multiplexing and Omics.Nature reviews. Methods primers · 2024Article
- Exploiting signaling rewiring in cancer cells with co-existing oncogenic drivers.Molecular oncology · 2023Article
- Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De NovoInternational journal of molecular sciences · 2023Article
- The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.Molecular cancer therapeutics · 2023Review
- Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer.British journal of cancer · 2023Article
- Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.Cancer discovery · 2023Article
- [Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Pınar Özden EserLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0003-1555-4981
Raymond M ParanalLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jieun SonLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-9862-7706
Elena IvanovaBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Yanan KuangBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-5416-5543
Heidi M HaikalaLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-8465-8568
Ciric ToLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-6333-3174
Jeffrey J OkoroLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0003-0094-5648
Kshiti H DholakiaLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-5807-0058
Jihyun ChoiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-9966-8294
Yoonji EumLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Atsuko OginoLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-9677-362X
Pavlos MissiosStem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA.
Dalia ErcanLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-2425-0691
Man XuBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Michael J PoitrasExperimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Stephen WangBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-5867-7386
Kenneth NgoBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-5511-2825
Michael DillsBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-7382-695X
Masahiko YanagitaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Timothy LopezLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Mika LinLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-1353-7590
Jeanelle TsaiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-0205-3494
Nicolas FlochOncology R&D, Bioscience, AstraZeneca, CRUK Cambridge Institute, Robinson Way, Cambridge CB2 0RE, UK.
Emily S ChambersLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0003-4076-506X
Jennifer HengLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-8263-6923
Rana AnjumBioscience, Oncology R&D, AstraZeneca, 25 Gatehouse Park, Waltham, MA 02451, USA.ORCID 0000-0002-5354-1797
Alison D SantucciLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-6648-2802
Kesi MichaelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-0899-9790
Alwin G SchullerBioscience, Oncology R&D, AstraZeneca, 25 Gatehouse Park, Waltham, MA 02451, USA.ORCID 0000-0001-9163-5885
Darren CrossGlobal Medical Affairs, Oncology Business Unit, AstraZeneca, 136 Hills Road, Cambridge CB2 8PA, UK.ORCID 0000-0002-5227-2871
Paul D SmithOncology R&D, Bioscience, AstraZeneca, CRUK Cambridge Institute, Robinson Way, Cambridge CB2 0RE, UK.ORCID 0000-0002-2812-5978
Geoffrey R OxnardLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
David A BarbieLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lynette M ShollDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-9532-9735
Magda BahcallLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-9888-1026
Sangeetha PalakurthiBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-7533-3243
Prafulla C GokhaleBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-1974-5921
Cloud P PaweletzBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
George Q DaleyHarvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-6346-5919
Pasi A JänneLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-7821-4928
Funding
RESEARCH TRAINING-MEDICAL INFORMATICS 90T15LM007092 · NLM · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI Nils Gehlenborg · 1992 to 2026
$32.8MDevelopment of Combination Therapies to Delay/Prevent Acquired Drug ResistanceR35CA220497 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2018 to 2024
$7.2MResistance and Sensitivity to MET Inhibitors in Lung CancerR01CA222823 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2018 to 2022
$1.9MEGFR T790M-mediated drug resistance in non-small cell lung cancerF31CA192623 · NCI · HARVARD MEDICAL SCHOOL · PI ESER, PINAR OZDEN · 2015 to 2017
$103kNCI NIH HHS F31 CA192623NCI NIH HHS R01 CA222823NCI NIH HHS R35 CA220497NLM NIH HHS T15 LM007092
Abstract
The clinical efficacy of epidermal growth factor receptor (EGFR)–targeted therapy in
Indexed as
ErbB ReceptorsLung NeoplasmsCell Line, TumorDrug Resistance, NeoplasmHumansMutationProtein Kinase InhibitorsEGFR protein, humanErbB ReceptorsProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.